



Number: VIE21-0523



EFFECTIVENESS OF CARBOXIMALTOSE IRON IN PREOPERATIVE ANAEMIA TREATMENT

Alonso Moreno M, Rodríguez Ramallo H, Pérez Blanco JL, Pérez Maroto MT, Mingot E, Rubio Romero R

BLACKGROUND AND IMPORTANCE



effectiveness of CII for surgical patients and to describe the transfusional requirements





N=70

CII Dose = 1274.3 g ± 352.5 **bHB**= 9.8 ± 1.2; **perioperative HB** = 11.0 ± 1.4 time between CII and the surgery: 37.7 ± 41.2 days.

carboxymaltose intravenous iron (CII) reduction of red correction of blood cell perioperative anemia transfusion (RBCT)

> **MATERIAL AND METHODS** 0

Observational retrospective unicentric study including surgical patients who received CII between

> January 2017 and December 2018. in a third level hospital.

Variables collected: sex, age, CII dose, baseline and perioperative haemoglobin (HB), time passed between the CII administration and the surgical procedure.

Effectiveness: percentage of patients with an increase in HB in preoperative stage compared to baseline HB (bHB) > 1 g/dL and the difference and number of transfusion after the surgical procedure.

Data were expressed: average ± standard deviation and the analysis test used was chi-square.



CONCLUSIONS AND RELEVANCE Q

CII has demonstrated clinical effectiveness due to an increase of HB in most of patients. In addition, CII administration has reduced RCBT of the included patients however, is necessary the design of a comparative study with a cohort of surgical patients without CII administration.

